MHC class I TCR engineered anti-tumor CD4 T cells: Implications for cancer immunotherapy

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 9, Issue 4, 2009, Pages 344-352

  Chhabra, Arvind ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cancer; Immunotherapy; MHC class I TCR engineered CD4 T cells

Indexed keywords

CANCER VACCINE; COMPLEMENTARY DNA; DENDRITIC CELL VACCINE; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RETROVIRUS VECTOR; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; NONHUMAN; REVIEW; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; AUTOANTIGENS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; CYTOKINES; GENETIC ENGINEERING; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY, ACTIVE; MICE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; TUMOR ESCAPE;

EID: 75749110973     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153009789839183     Document Type: Review

References (77)

1. Burnet, M. (1957) Cancer; a biological approach. I: the processes of control. Br. Med. J., 1, 779-786.
2. Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J. and Schreiber, R.D. (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol., 3, 991-998.
3. Mukherji, B. and MacAlister, T.J. (1983) Clonal analysis of cytotoxic T cell response against human melanoma. J. Exp. Med., 158, 240-245.
4. de Vries, J.E. and Spits, H. (1984) Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity. J. Immunol., 132, 510-519.
5. Knuth, A.; Danowski, B.; Oettgen, H.F. and Old, L.J. (1984) Tcell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc. Natl. Acad. Sci. USA, 81, 3511-3515.
6. van der Bruggen, P.; Traversari, C.; Chomez, P.; Lurquin, C.; De Plaen, E.; Van den Eynde, B.; Knuth, A. and Boon, T. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254, 1643-1647.
7. Novellino, L.; Castelli, C. and Parmiani, G. (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother., 54, 187-207.
8. Steinman, R.M. (1991) The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9, 271-296.
9. Inaba, K.; Inaba, M.; Romani, N.; Aya, H.; Deguchi, M.; Ikehara, S.; Muramatsu, S. and Steinman, R.M. (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med., 176, 1693-1702.
10. Sallusto, F. and Lanzavecchia, A. (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med., 179, 1109-1118.
11. Timmerman, J.M. and Levy, R. (1999) Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med., 50, 507-529.
12. Rosenberg, S.A. (2001) Progress in human tumour immunology and immunotherapy. Nature, 411, 380-384.
13. Rosenberg, S.A.; Yang, J.C. and Restifo, N.P. (2004) Cancer immunotherapy: moving beyond current vaccines. Nat. Med., 10, 909-915.
14. Gilboa, E. (2007) DC-based cancer vaccines. J. Clin. Invest., 117, 1195-1203.
15. Altman, J.D.; Moss, P.A.; Goulder, P.J.; Barouch, D.H.; McHeyzer-Williams, M.G.; Bell, J.I.; McMichael, A.J. and Davis, M.M. (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science, 274, 94-96.
16. Southam, C.M.; Brunschwig, A; Levin, A.G. and Dizon, Q.S. (1966) Effect of leukocytes on transplantability of human cancer. Cancer, 19, 1743-1753.
17. Schuler, G.; Schuler-Thurner, B. and Steinman, R.M. (2003) The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol., 15, 138-147.
18. Banchereau, J.; Fay, J.; Paczesny, S.; Ueno, H.; Dhodapkarz, M. and Palucka, A.K. (2004) Dendritic cells as melanoma vaccines. Dev. Biol. (Basel), 116, 147-156; discussion 179-186.
19. Marchand, M.; van Baren, N.; Weynants, P.; Brichard, V.; Dreno, B.; Tessier, M.H.; Rankin, E.; Parmiani, G.; Arienti, Y.; Humblet, A.; Bourlond, R.; Vanwijck, D.; Lienard, M.; Beauduin, P.; Dietrich, Y.; Russo, V.; Kerger, J.; Masucci, G.; Jager, E.; De Greve, J.; Atzpodien, J.; Brasseur, F.; Coulie, P.G.; van der Bruggen, P. and Boon, T. (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer, 80, 219-230.
20. Wang, F.; Bade, E.; Kuniyoshi, C.; Spears, L.; Jeffery, G.; Marty, V.; Groshen, S. and Weber, J. (1999) Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res., 5, 2756-2765.
21. Mukherji, B.; Chakraborty, N.G.; Yamasaki, S.; Okino, T.; Yamase, H.; Sporn, J.R.; Kurtzman, S.K.; Ergin, M.T.; Ozols, J.; Meehan, J. and Mauri, F. (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA, 92, 8078-8082.
22. Hsu, F.J.; Benike, C.; Fagnoni, F.; Liles, T.M.; Czerwinski, D.; Taidi, B.; Engleman, E.G. and Levy, R. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2, 52-58.
23. Chakraborty, N.G.; Sporn, J.R.; Tortora, A.F.; Kurtzman, S.H.; Yamase, H.; Ergin, M.T. and Mukherji, B. (1998) Immunization with a tumor-cell-lysate- loaded autologous-antigen-presenting-cellbased vaccine in melanoma. Cancer Immunol. Immunother., 47, 58-64.
24. Dranoff, G. (2002) GM-CSF-based cancer vaccines. Immunol. Rev., 188, 147-154.
25. Ribas, A.; Butterfield, L.H.; McBride, W.H.; Jilani, S.M.; Bui, L.A.; Vollmer, C.M.; Lau, R.; Dissette, V.B.; Hu, B.; Chen, A.Y.; Glaspy, J.A. and Economou, J.S. (1997) Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res., 57, 2865-2869.
26. Chhabra, A.; Mehrotra, S.; Chakraborty, N.G.; Mukherji, B. and Dorsky, D.I. (2004) Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation. Eur. J. Immunol., 34, 2824-2833.
27. Breckpot, K.; Emeagi, P.U. and Thielemans, K. (2008) Lentiviral vectors for anti-tumor immunotherapy. Curr. Gene Ther., 8, 438-448.
28. Nair, S.K.; Boczkowski, D.; Morse, M.; Cumming, R.I.; Lyerly, H.K. and Gilboa, E. (1998) Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol., 16, 364-369.
29. Van Tendeloo, V.F.; Ponsaerts, P.; Lardon, F.; Nijs, G.; Lenjou, M.; Van Broeckhoven, C.; Van Bockstaele, D.R. and Berneman, Z.N. (2001) Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood, 98, 49-56.
30. Mitchison, N.A. (1955) Studies on the immunological response to foreign tumor transplants in the mouse. I: the role of lymph node cells in conferring immunity by adoptive transfer. J. Exp. Med., 102, 157-177.
31. Grimm, E.A.; Mazumder, A.; Zhang, H.Z. and Rosenberg, S.A. (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med., 155, 1823-1841.
32. Rosenberg, S.A.; Lotze, M.T.; Muul, L.M.; Leitman, S.; Chang, A.E.; Ettinghausen, S.E.; Matory, Y.L; Skibber, J.M.; Shiloni, E.; Vetto, J.T.; Seipp, C.A.; Simpson, C. and Reichert, C.M. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med., 313, 1485-1492.
33. Rosenberg, S.A.; Spiess, P. and Lafreniere, R. (1986) A new approach to the adoptive immunotherapy of cancer with tumorinfiltrating lymphocytes. Science, 233, 1318-1321.
34. Yee, C.; Thompson, J.A.; Byrd, D.; Riddell, S.R.; Roche, P.; Celis, E. and Greenberg, P.D. (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA, 99, 16168-16173.
35. Dudley, M.E.; Wunderlich, J.R.; Yang, J.C.; Sherry, R.M.; Topalian, S.L.; Restifo, N.P.; Royal, R.E.; Kammula, U.; White, D.E.; Mavroukakis, S.A.; Rogers, L.J.; Gracia, G.J.; Jones, S.A.; Mangiameli, D.P.; Pelletier, M.M.; Gea-Banacloche, J.; Robinson, M.R.; Berman, D.M.; Filie, A.C.; Abati, A. and Rosenberg, S.A. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol., 23, 2346-2357.
36. Holmberg, L.; Kikuchi, K.; Gooley, T.A.; Adams, K.M.; Hockenbery, D.M.; Flowers, M.E.; Schoch, H.G.; Bensinger, W. and McDonald, G.B. (2006) Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. Biol. Blood Marrow Transplant., 12, 226-234.
37. Dudley, M.E.; Wunderlich, J.R.; Shelton, T.E.; Even, J. and Rosenberg, S.A. (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother., 26, 332-342.
38. Dembic, Z.; Haas, W.; Weiss, S.; McCubrey, J.; Kiefer, H.; von Boehmer, H. and Steinmetz, M. (1986) Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature, 320, 232-238.
39. Cooper, L.J.; Kalos, M.; Lewinsohn, D.A.; Riddell, S.R. and Greenberg, P.D. (2000) Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol., 74, 8207-8212.
40. Orentas, R.J.; Roskopf, S.J.; Nolan, G.P. and Nishimura, M.I. (2001) Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin. Immunol., 98, 220-228.
41. Clay, T.M.; Custer, M.C.; Sachs, J.; Hwu, P.; Rosenberg, S.A. and Nishimura, M.I. (1999) Efficient transfer of a tumor antigenreactive TCR to human peripheral blood lymphocytes confers antitumor reactivity. J. Immunol., 163, 507-513.
42. Kessels, H.W.; Wolkers, M.C.; van den Boom, M.D.; van der Valk, M.A. and Schumacher, T.N. (2001) Immunotherapy through TCR gene transfer. Nat. Immunol., 2, 957-961.
43. Schumacher, T.N. (2002) T-cell-receptor gene therapy. Nat. Rev. Immunol., 2, 512-519.
44. Cole, D.J.; Weil, D.P.; Shilyansky, J.; Custer, M.; Kawakami, Y.; Rosenberg, S.A. and Nishimura, M.I. (1995) Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res., 55, 748-752.
45. Heemskerk, M.H.; Hoogeboom, M.; Hagedoorn, R.; Kester, M.G.; Willemze, R. and Falkenburg, J.H. (2004) Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J. Exp Med., 199, 885-894.
46. Morgan, R.A.; Dudley, M.E.; Wunderlich, J.R.; Hughes, M.S.; Yang, J.C.; Sherry, R.M.; Royal, R.E.; Topalian, S.L.; Kammula, U.S.; Restifo, N.P.; Zheng, Z.; Nahvi, A.; de Vries, C.R.; Rogers-Freezer, L.J.; Mavroukakis, S.A. and Rosenberg, S.A. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314, 126-129.
47. Cohen, C.J.; Zhao, Y.; Zheng, Z.; Rosenberg, S.A. and Morgan, R.A. (2006) Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res., 66, 8878-8886.
48. Cohen, C.J.; Li, Y.F.; El-Gamil, M.; Robbins, P.F.; Rosenberg, S.A. and Morgan, R.A. (2007) Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res., 67, 3898-3903.
49. Edelstein, M.L.; Abedi, M.R.; Wixon, J. and Edelstein, R.M. (2004) Gene therapy clinical trials worldwide 1989-2004-an overview. J. Gene Med., 6, 597-602.
50. Hacein-Bey-Abina, S.; von Kalle, C.; Schmidt, M.; Le Deist, F.; Wulffraat, N.; McIntyre, E.; Radford, I.; Villeval, J.L.; Fraser, C.C.; Cavazzana-Calvo, M. and Fischer, A. (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 348, 255-256.
51. Keene, J.A. and Forman, J. (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp Med., 155, 768-782.
52. Bevan, M.J. (2004) Helping the CD8(+) T-cell response. Nat. Rev. Immunol., 4, 595-602.
53. Beuneu, H.; Garcia, Z. and Bousso, P. (2006) Cutting edge: cognate CD4 help promotes recruitment of antigen-specific CD8 T cells around dendritic cells. J. Immunol., 177, 1406-1410.
54. Cohen, P.A.; Peng, L.; Plautz, G.E.; Kim, J.A.; Weng, D.E. and Shu, S. (2000) CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit. Rev. Immunol., 20, 17-56.
55. Bennett, S.R.; Carbone, F.R.; Karamalis, F.; Flavell, R.A.; Miller, and Heath, W.R. (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature, 393, 478-480.
56. Lanzavecchia, A. (1998) Immunology. Licence to kill. Nature, 393, 413-414.
57. Kennedy, R. and Celis, E. (2006) T helper lymphocytes rescue CTL from activation-induced cell death. J. Immunol., 177, 2862-2872.
58. Marzo, A.L.; Kinnear, B.F.; Lake, R.A.; Frelinger, J.J.; Collins, E.J.; Robinson, B.W. and Scott, B. (2000) Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated antitumor immunity. J. Immunol., 165, 6047-6055.
59. Hung, K.; Hayashi, R.; Lafond-Walker, A.; Lowenstein, C.; Pardoll, D. and Levitsky, H. (1998) The central role of CD4(+) T cells in the antitumor immune response. J. Exp Med., 188, 2357-2368.
60. Hunder, N.N.; Wallen, H.; Cao, J.; Hendricks, D.W.; Reilly, J.Z.; Rodmyre, R.; Jungbluth, A.; Gnjatic, S.; Thompson, J.A. and Yee, C. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med., 358, 2698-2703.
61. Alexander, J.; Sidney, J.; Southwood, S.; Ruppert, J.; Oseroff, C.; Maewal, A.; Snoke, K.; Serra, H.M.; Kubo, R.T.; Sette, A. and Grey, H.M. (1994) Development of high potency universal DRrestricted helper epitopes by modification of high affinity DRblocking peptides. Immunity, 1, 751-761.
62. Perez-Diez, A.; Butterfield, L.H.; Li, L.; Chakraborty, N.G.; Economou, J.S. and Mukherji, B. (1998) Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res., 58, 5305-5309.
63. Chhabra, A.; Yang, L.; Wang, P.; Comin-Anduix, B.; Das, R.; Chakraborty, N.G.; Ray, S.; Mehrotra, S.; Yang, H.; Hardee, C.L.; Hollis, R.; Dorsky, D.I.; Koya, R.; Kohn, D.B.; Ribas, A.; Economou, J.S.; Baltimore, D. and Mukherji, B. (2008) CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J. Immunol., 181, 1063-1070.
64. Hughes, M.S.; Yu, Y.Y.; Dudley, M.E.; Zheng, Z.; Robbins, P.F.; Li, Y.; Wunderlich, J.; Hawley, R.G.; Moayeri, M.; Rosenberg, S.A. and Morgan, R.A. (2005) Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene. Ther., 16, 457-472.
65. Zhao, Y.; Zheng, Z.; Robbins, P.F.; Khong, H.T.; Rosenberg, S.A. and Morgan, R.A. (2005) Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol., 174, 4415-4423.
66. Johnson, L.A.; Heemskerk, B.; Powell, D.J.; Cohen, C.J.; Jr.; Morgan, R.A.; Dudley, M.E.; Robbins, P.F. and Rosenberg, S.A. (2006) Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol., 177, 6548-6559.
67. Roszkowski, J.J.; Lyons, G.E.; Kast, W.M.; Yee, C.; Van Besien, K. and Nishimura, M.I. (2005) Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res., 65, 1570-1576.
68. Willemsen, R.; Ronteltap, C.; Heuveling, M.; Debets, R. and Bolhuis, R. (2005) Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha. Gene Ther., 12, 140-146.
69. Tsuji, T.; Yasukawa, M.; Matsuzaki, J.; Ohkuri, T.; Chamoto, K.; Wakita, D.; Azuma, T.; Niiya, H.; Miyoshi, H.; Kuzushima, K.; Oka, Y.; Sugiyama, H.; Ikeda, H. and Nishimura, T. (2005) Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood, 106, 470-476.
70. Chamoto, K.; Tsuji, T.; Funamoto, H.; Kosaka, A.; Matsuzaki, J.; Sato, T.; Abe, H.; Fujio, K.; Yamamoto, K.; Kitamura, T.; Takeshima, T.; Togashi, Y. and Nishimura, T. (2004) Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res., 64, 386-390.
71. Wang, H.Y. and Wang, R.F. (2007) Regulatory T cells and cancer. Curr. Opin. Immunol., 19, 217-223.
72. Whiteside, T.L. (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene, 27, 5904-5912.
73. Dhodapkar, M.V.; Dhodapkar, K.M. and Palucka, A.K. (2008) Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ., 15, 39-50.
74. Stewart, T.J. and Abrams, S.I. (2008) How tumours escape mass destruction. Oncogene, 27, 5894-5903.
75. Yang, W.; Chen, P.W.; Li, H.; Alizadeh, H. and Niederkorn, J.Y. (2008) PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest. Ophthalmol. Vis. Sci., 49, 2518-2525.
76. Yuan, J.; Gnjatic, S.; Li, H.; Powel, S.; Gallardo, H.F.; Ritter, E.; Ku, G.Y.; Jungbluth, A.A.; Segal, N.H.; Rasalan, T.S.; Manukian, G.; Xu, Y.; Roman, R.A.; Terzulli, S.L.; Heywood, M.; Pogoriler, E.; Ritter, G.; Old, L.J.; Allison, J.P. and Wolchok, J.D. (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. USA, 105, 20410-20415.
77. Wong, S.B.; Bos, R. and Sherman, L.A. (2008) Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J. Immunol., 180, 3122-3131.